|
Volumn 165, Issue 2, 2008, Pages 166-168
|
Magnetic resonance imaging and late-life depression: Potential biomarkers in the era of personalized medicine
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ESCITALOPRAM;
CITALOPRAM;
PHARMACOLOGICAL BIOMARKER;
SEROTONIN UPTAKE INHIBITOR;
UNCLASSIFIED DRUG;
ANISOTROPY;
BEHAVIOR DISORDER;
BRAIN REGION;
COGNITIVE DEFECT;
DIFFUSION TENSOR IMAGING;
EDITORIAL;
FUNCTIONAL MAGNETIC RESONANCE IMAGING;
HEMISPHERE;
HUMAN;
MAJOR DEPRESSION;
MENTAL DISEASE;
MOOD DISORDER;
MORPHOMETRICS;
NERVE CELL NETWORK;
NERVE FIBER;
NEUROBIOLOGY;
NEUROIMAGING;
NEUROSCIENCE;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PATHOPHYSIOLOGY;
PRIORITY JOURNAL;
WHITE MATTER;
AGE;
BODY WATER;
BRAIN;
DIFFUSION WEIGHTED IMAGING;
DRUG DESIGN;
METABOLISM;
METHODOLOGY;
NOTE;
STATISTICS;
ULTRASTRUCTURE;
AGE FACTORS;
ANISOTROPY;
BIOMARKERS, PHARMACOLOGICAL;
BODY WATER;
BRAIN;
CITALOPRAM;
DEPRESSIVE DISORDER, MAJOR;
DIFFUSION MAGNETIC RESONANCE IMAGING;
DRUG DESIGN;
HUMANS;
MAGNETIC RESONANCE IMAGING;
SEROTONIN UPTAKE INHIBITORS;
|
EID: 40949130827
PISSN: 0002953X
EISSN: None
Source Type: Journal
DOI: 10.1176/appi.ajp.2007.07111771 Document Type: Editorial |
Times cited : (10)
|
References (10)
|